From PharmTech: Detecting and Determining Quantitation Limits for Impurities

News
Article
In the Lab eNewsletterPharmaceutical Technology's In the Lab eNewsletter, December 2021
Volume 16
Issue 12

Different methods to calculate limits for impurities will give different answers. The prediction interval method may be ideal.

Regulations require drug manufacturers determine the detection limit (DL) and quantitation limit (QL) of impurities in APIs and drug products. There are multiple ways of doing so, some of which are described in the International Conference on Harmonisation (ICH) guideline, ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology. Primarily, these methods are based upon the statistical uncertainties from a linear least squares regression calibration curve. However, different calculation methods give different answers. The following describes an example and a recommended best practice method.

View the original article published in the November 2021 issue of Pharmaceutical Technology.

About the Author

Chris Burgess is managing director, Burgess Analytical Consultancy Limited, Barnard Castle, Co Durham, UK.

Recent Videos
Drug Digest: Strategic Partnerships
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development